2024预见ASCO｜妇科肿瘤领域重磅研究一览

前言

一年一度的全球肿瘤界盛会——美国临床肿瘤学会（ASCO）年会将于当地时间5月31日-6月4日召开。医脉通特梳理了妇科肿瘤领域的部分重磅研究进展。一起来看下吧！

Gynecologic Cancer

妇科肿瘤

快速口头报告

当地时间：

6月1日 – GMT-5 08:00

北京时间：

6月1日 – GMT+8 21:00

E451

01

摘要号：5512

信迪利单抗联合紫杉醇和顺铂作为局部晚期宫颈癌新辅助治疗的有效性和安全性：一项II期研究

标题：Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.

报告人：刘继红教授

单位：中山大学肿瘤防治中心

02

摘要号：5513

开放标签、单臂、II期、多中心试验（DURBAC）：度伐利尤单抗和BVAC-C治疗一线铂类化疗失败的HPV 16或18阳性宫颈癌

标题：An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).

报告人：Chel Hun Choi, MD, PhD

单位：Department of Obstetrics and Gynecology, Samsung Medical Center

03

摘要号：5514

随机、III期CC3研究：尼妥珠单抗联合同步放化疗治疗局部晚期宫颈鳞状细胞癌

标题：Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study.

报告人：王俊杰教授

单位：北京大学第三医院

04

摘要号：LBA5515

III期、随机、双盲、安慰剂/紫杉醇对照AXLerate-OC/GOG-3059/ENGOT OV-66研究：batiraxcept（AVB-S6-500）联合紫杉醇治疗铂耐药复发性卵巢癌

标题：AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

报告人：Katherine Cynthia Fuh, MD, PhD

单位：University of California, San Francisco

05

摘要号：LBA5516

suvemcitug联合化疗治疗铂类耐药卵巢癌的随机、双盲、安慰剂对照III期研究（SCORES）

标题：A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).

报告人：袁光文教授

单位：中国医学科学院肿瘤医院

06

摘要号：5517

口服环磷酰胺联合贝伐珠单抗治疗复发性卵巢癌、输卵管癌和原发性腹膜癌

标题：Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.

报告人：Mostafa Eyada

单位：University of Texas Medical Branch

07

摘要号：5518

一项随机试验中肿瘤干细胞功能分析与复发性铂耐药卵巢癌患者客观缓解率的关系

标题：Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial.

报告人：Thomas J. Herzog, MD

单位：University of Cincinnati

08

摘要号：5519

腹膜内化疗的优化:随机II期GERCOR CHIMOVIP研究

标题：Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.

报告人：Romain Cohen, MD, PhD

单位：Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP

09

摘要号：5520

多中心、开放标签、随机、III期研究（SOC-1）的最终总生存期分析：二次减瘤术后序贯化疗对比单纯化疗治疗铂敏感复发性卵巢癌

标题：Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.

报告人：臧荣余教授

单位：复旦大学附属中山医院

Gynecologic Cancer

妇科肿瘤

口头报告

当地时间：

6月2日 – GMT-5 08:00

北京时间：

6月2日 – GMT+8 21:00

Hall D2

01

摘要号：LBA5500

随机II期BrUOG 354的最终结果：纳武利尤单抗单药或联合伊匹木单抗治疗卵巢和其他肾外透明细胞癌

标题：Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.

报告人：Don S. Dizon, MD, FASCO, FACP

单位：Lifespan Cancer Institute, Rhode Island Hospital

02

摘要号：LBA5501

阿替利珠单抗与安慰剂联合贝伐珠单抗和非铂类化疗治疗复发性卵巢癌的比较：来自AGO-OVAR 2.29/ENGOT-ov34研究的最终总生存期和无进展生存期结果

标题：Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

报告人：Frederik Marmé, MD, PhD

单位：Heidelberg University, University Hospital Mannheim

03

摘要号：5502

Vibostolimab联合帕博利珠单抗治疗经治的晚期错配修复缺陷（dMMR）子宫内膜癌：II期KEYVIBE-005研究队列B1的结果

标题：Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.

报告人：Carlos Rojas, MD

单位：Bradford Hill Clinical Research Center

04

摘要号：5503

靶向治疗的III期妇科临床试验趋势：过去12年的研究监督和药物参与

标题：Trends in phase 3 gynecological clinical trials of targeted therapies: Study oversight and pharmaceutical involvement in the past 12 years.

报告人：Qiao Ruan, MD

单位：California Pacific Medical Center

05

摘要号：5504

根治性子宫切除术后高危早期宫颈癌患者同步放化疗（CRT）后的辅助化疗：NRG oncology/RTOG 0724/GOG-0724的结果

标题：Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.

报告人：Anuja Jhingran, MD

单位：The University of Texas MD Anderson Cancer Center

06

摘要号：LBA5505

随机III期CARACO研究：新辅助化疗后接受初次或间期肿瘤细胞减灭术的晚期上皮性卵巢癌患者不进行淋巴结切除术

标题：Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.

报告人：Jean-Marc Classe, MD, PhD

单位：Nantes Université

07

摘要号：5506

II期、随机、多中心NEO研究：奥拉帕利新辅助治疗铂敏感复发性高级别浆液性卵巢癌

标题：Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.

报告人：Stephanie Lheureux, MD, PhD

单位：Princess Margaret, University Health Network

08

摘要号：5507

21世纪美国子宫内膜癌和肥胖的趋势

标题：Endometrial cancer and obesity trends in the United States in the 21st century.

报告人：Alex Andrea Francoeur, MD

单位：UC Irvine Health

09

摘要号：5508

绝经前临床I期子宫内膜癌患者激素治疗的长期生存预后

标题：Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.

报告人：Yukio Suzuki, MD, PhD

单位：Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons

备注：排名不分先后，按照摘要号进行

如有遗漏或任何问题，请给我们留言~

参考来源：https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/scheduled-sessions

编辑：Uni

排版：Uni

执行：Uni

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。